Bordetella infection

2020 ◽  
pp. 1073-1076
Author(s):  
Cameron C. Grant
Keyword(s):  
Bordetella Pertussis ◽  
Whooping Cough ◽  
Severe Disease ◽  
Diagnostic Methods ◽  
Illness Onset ◽  
Young Infants ◽  
Adolescents And Adults ◽  
Risk Of Exposure ◽  
Acellular Vaccines ◽  
Infectious Organism

Bordetella are small Gram-negative coccobacilli, of which Bordetella pertussis is the most important human pathogen. Bordetella pertussis is the cause of whooping cough, which remains one of the 10 leading causes of death among children less than five years old. Transmission of this highly infectious organism is primarily by aerosolized droplets. The preferred diagnostic methods are polymerase chain reaction detection from nasopharyngeal samples and serology (IgG antibodies to pertussis toxin). Macrolide antibiotics are recommended if started within four weeks of illness onset. Preventing severe disease in young children remains the primary goal, hence schedules consist of a three-dose infant series and subsequent booster doses. Acellular vaccines enable immunization schedules to include adolescents and adults. Acellular pertussis vaccine given to pregnant women reduces the risk of pertussis in young infants. Antibiotic prophylaxis is given when there is an infant at risk of exposure.

Pertussis

2021 ◽  
Author(s):  
Carl Heinz Wirsing von König
Keyword(s):  
Whooping Cough ◽  
Severe Disease ◽  
Newborn Infants ◽  
School Entry ◽  
Whole Cell ◽  
Young Infants ◽  
Combination Vaccines ◽  
Adolescents And Adults ◽  
Second Year ◽  
Acellular Vaccines

The bacterium Bordetella pertussis causes disease by producing various virulence and adhesion factors, among them pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN) and agglutinogens (Agg), also called fimbriae (FIM) "Typical" pertussis or whooping cough starts with unspecific respiratory symptoms (catarrhal phase) followed by severe coughing spasms with whoops and vomiting (paroxysmal phase) and only after weeks or months disease severity slowly wanes (convalescent phase). "Atypical pertussis" with unspecific, long-lasting coughing episodes is seen in adolescents and adults; very young infants may die from apnoea. B. pertussis is transmitted by droplets, and neither infection nor vaccination produce long lasting protection. Macrolide antibiotics are given to patients and their contacts to reduce spread of the organism; however, antibiotics do NOT change the duration or course of the disease once symptoms are present. Whole cell pertussis vaccines (wP) consist of whole inactivated B. pertussis-cells, whereas acellular vaccines (aP) consist of one to five single components like PT, FHA, PRN or FIM. Pertussis vaccines are currently only available as combination vaccines with tetanus und diphtheria (DTP). Among these are DTwP; DTaP; TdaP; and various DTP-combinations with Hib, IPV, HBV vaccines. Whole cell pertussis (DTwP) combination vaccines are more reactogenic, whereas DTaP vaccines are generally well tolerated. Some DTwP had good efficacy/effectiveness (90%), it was low (40%) with others. Vaccine efficacy of DTaP vaccines ranges between 70% and 90%. As with most vaccines, efficiency is higher for severe disease. While pertussis vaccines did control clinical disease, protection is limited. Vaccination is recommended for all infants (three doses) worldwide with a booster in the second year of life. Many countries give additional doses at school entry and in adolescents, and some to adults. Vaccination of pregnant women effectively protects newborn infants and is increasingly recommended.

Pertussis

2021 ◽  
Author(s):  
Carl Heinz Wirsing von König
Keyword(s):  
Whooping Cough ◽  
Severe Disease ◽  
Newborn Infants ◽  
School Entry ◽  
Whole Cell ◽  
Young Infants ◽  
Combination Vaccines ◽  
Adolescents And Adults ◽  
Second Year ◽  
Acellular Vaccines

The bacterium Bordetella pertussis causes disease by producing various virulence and adhesion factors, among them pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN) and agglutinogens (Agg), also called fimbriae (FIM) "Typical" pertussis or whooping cough starts with unspecific respiratory symptoms (catarrhal phase) followed by severe coughing spasms with whoops and vomiting (paroxysmal phase) and only after weeks or months disease severity slowly wanes (convalescent phase). "Atypical pertussis" with unspecific, long-lasting coughing episodes is seen in adolescents and adults; very young infants may die from apnoea. B. pertussis is transmitted by droplets, and neither infection nor vaccination produce long lasting protection. Macrolide antibiotics are given to patients and their contacts to reduce spread of the organism; however, antibiotics do NOT change the duration or course of the disease once symptoms are present. Whole cell pertussis vaccines (wP) consist of whole inactivated B. pertussis-cells, whereas acellular vaccines (aP) consist of one to five single components like PT, FHA, PRN or FIM. Pertussis vaccines are currently only available as combination vaccines with tetanus und diphtheria (DTP). Among these are DTwP; DTaP; TdaP; and various DTP-combinations with Hib, IPV, HBV vaccines. Whole cell pertussis (DTwP) combination vaccines are more reactogenic, whereas DTaP vaccines are generally well tolerated. Some DTwP had good efficacy/effectiveness (90%), it was low (40%) with others. Vaccine efficacy of DTaP vaccines ranges between 70% and 90%. As with most vaccines, efficiency is higher for severe disease. While pertussis vaccines did control clinical disease, protection is limited. Vaccination is recommended for all infants (three doses) worldwide with a booster in the second year of life. Many countries give additional doses at school entry and in adolescents, and some to adults. Vaccination of pregnant women effectively protects newborn infants and is increasingly recommended.

Cleft Nucleus Lymphocytosis in Young Infants with Pertussis

2020 ◽  
Author(s):  
Huifang Zhu ◽  
Hongqun Liao ◽  
Xiaoming Zhong ◽  
Xingyu Rao ◽  
Xin Yang ◽  
...  
Keyword(s):  
Young Children ◽  
Bordetella Pertussis ◽  
Whooping Cough ◽  
Pediatric Intensive Care ◽  
Peripheral Blood Smear ◽  
Significant Rise ◽  
Enzyme Linked Immunosorbent Assay ◽  
Respiratory Pathogens ◽  
Pertussis Infection ◽  
Young Infants

AbstractThis study aims to assess whether the cleft nucleus lymphocytosis could be an early promising clue for the diagnosis of pertussis in young infants. Pertussis (whooping cough) is a severe respiratory disease mainly caused by Bordetella pertussis infection and is characterized by a significant rise in the number of leukocyte and lymphocyte in infants and young children. In this study, the Bordetella pertussis DNA was detected from samples of pharyngeal swab by PCR assay. Levels of serum specific IgM against other respiratory pathogens were detected by Enzyme-linked immunosorbent assay (ELISA) assay. The routine blood test including numbers of leukocytes, lymphocytes, and platelets etc. were tested by automatic hemocyte analyzer (Sysemx XN1000). Besides, the morphology of leucocytes was observed in peripheral blood smear with microscope by Wright-Giemsa stain. Three cases of pertussis with cleft nucleus lymphocytes in young infants were discussed in in the neonatal/pediatric intensive care unit in our hospital. Leukocytosis characterized by lymphocytes, as well as thrombocytosis were observed in all patients. Our results demonstrated that cleft nucleus lymphocytosis accompanied with leukocytosis and lymphocytes would be potent assistant indicators for the early diagnosis of pertussis in young children.

scholarly journals Global Population Structure and Evolution of Bordetella pertussis and Their Relationship with Vaccination

mBio ◽  
2014 ◽  
Vol 5 (2) ◽  
Author(s):  
Marieke J. Bart ◽  
Simon R. Harris ◽  
Abdolreza Advani ◽  
Yoshichika Arakawa ◽  
Daniela Bottero ◽  
...  
Keyword(s):  
Bordetella Pertussis ◽  
Whooping Cough ◽  
Vaccine Coverage ◽  
Physiological Role ◽  
Toxin Production ◽  
Content Type ◽  
Vaccine Introduction ◽  
Worldwide Population ◽  
Genes Encoding ◽  
Acellular Vaccines

ABSTRACTBordetella pertussiscauses pertussis, a respiratory disease that is most severe for infants. Vaccination was introduced in the 1950s, and in recent years, a resurgence of disease was observed worldwide, with significant mortality in infants. Possible causes for this include the switch from whole-cell vaccines (WCVs) to less effective acellular vaccines (ACVs), waning immunity, and pathogen adaptation. Pathogen adaptation is suggested by antigenic divergence between vaccine strains and circulating strains and by the emergence of strains with increased pertussis toxin production. We applied comparative genomics to a worldwide collection of 343B. pertussisstrains isolated between 1920 and 2010. The global phylogeny showed two deep branches; the largest of these contained 98% of all strains, and its expansion correlated temporally with the first descriptions of pertussis outbreaks in Europe in the 16th century. We found little evidence of recent geographical clustering of the strains within this lineage, suggesting rapid strain flow between countries. We observed that changes in genes encoding proteins implicated in protective immunity that are included in ACVs occurred after the introduction of WCVs but before the switch to ACVs. Furthermore, our analyses consistently suggested that virulence-associated genes and genes coding for surface-exposed proteins were involved in adaptation. However, many of the putative adaptive loci identified have a physiological role, and further studies of these loci may reveal less obvious ways in whichB. pertussisand the host interact. This work provides insight into ways in which pathogens may adapt to vaccination and suggests ways to improve pertussis vaccines.IMPORTANCEWhooping cough is mainly caused byBordetella pertussis, and current vaccines are targeted against this organism. Recently, there have been increasing outbreaks of whooping cough, even where vaccine coverage is high. Analysis of the genomes of 343B. pertussisisolates from around the world over the last 100 years suggests that the organism has emerged within the last 500 years, consistent with historical records. We show that global transmission of new strains is very rapid and that the worldwide population ofB. pertussisis evolving in response to vaccine introduction, potentially enabling vaccine escape.

scholarly journals A qPCR assay for Bordetella pertussis cells that enumerates both live and dead bacteria

2019 ◽  
Author(s):  
Stacy Ramkissoon ◽  
Iain MacArthur ◽  
Muktar Ibrahim ◽  
Hans de Graaf ◽  
Robert C. Read ◽  
...  
Keyword(s):  
Causative Agent ◽  
Bordetella Pertussis ◽  
Whooping Cough ◽  
Quantitative Measure ◽  
Qpcr Assay ◽  
Whole Cell ◽  
Correlates Of Protection ◽  
Immune Correlates ◽  
Acellular Vaccines ◽  
Future Utility

AbstractBordetella pertussis is the causative agent of whooping cough, commonly referred to as pertussis. Although the incidence of pertussis was reduced through vaccination, during the last thirty years it has returned to high levels in a number of countries. This resurgence has been linked to the switch from the use of whole-cell to acellular vaccines. Protection afforded by acellular vaccines appears to be short-lived compared to that afforded by whole cell vaccines. In order to inform future vaccine improvement by identifying immune correlates of protection, a human challenge model of B. pertussis colonisation has been developed. Accurate measurement of colonisation status in this model has required development of a qPCR-based assay to enumerate B. pertussis in samples that distinguishes between viable and dead bacteria. Here we report the development of this assay and its performance in the quantification of B. pertussis from human challenge model samples. This assay has future utility in diagnostic labs and in research where a quantitative measure of both B. pertussis number and viability is required.

Bordetella infection

2010 ◽  
pp. 764-767
Author(s):  
Cameron Grant
Keyword(s):  
Pulmonary Hypertension ◽  
Clinical Features ◽  
Bordetella Pertussis ◽  
Whooping Cough ◽  
Human Pathogen ◽  
Gram Negative ◽  
Sputum Production ◽  
Childhood Death ◽  
Previous Infection ◽  
Infectious Organism

Bordetella are small Gram-negative coccobacilli, of which Bordetella pertussis is the most important human pathogen. It is the cause of whooping cough, which is one of the 10 leading causes of childhood death. Transmission of this highly infectious organism is primarily by aerosolized droplets. Clinical features—presentation varies with age, immunization and previous infection: (1) infants—apnoea, cyanosis, and paroxysmal cough; (2) nonimmunized children—cough, increasing in severity with distressing, repeated, forceful expirations followed by a gasping inhalation (the ‘whoop’); (3) children immunized in infancy—whooping, vomiting, sputum production; (4) adults—cough, post-tussive vomiting. Atypical mild illness is common. Complications include pneumonia, pulmonary hypertension, seizures and encephalopathy. Most deaths occur in those less than 2 months old....

scholarly journals A Bordetella pertussis-antitestek szeroprevalenciája magyarországi felnőttekben

2018 ◽  
Vol 159 (13) ◽  
pp. 503-510
Author(s):  
Péter Torzsa ◽  
Devadiga Raghavendra ◽  
Monica Tafalla
Keyword(s):  
Bordetella Pertussis ◽  
Whooping Cough ◽  
Acute Respiratory Tract Infection ◽  
Enzyme Linked Immunosorbent Assay ◽  
Igg Antibody ◽  
Recent Infection ◽  
Pertussis Infection ◽  
Young Infants ◽  
One Year ◽  
Antibody Levels

Abstract: Introduction: Pertussis (whooping cough) is an acute respiratory tract infection caused by Bordetella pertussis that is characterized by a chronic, severe cough. The optimum immunization schedule for pertussis is unclear, so these vary by countries. Aim: To estimate the seroprevalence of pertussis in adults in Hungary. Method: Serum anti-pertussis toxin immunoglobulin G (anti-PT IgG) antibody levels were analyzed using enzyme-linked immunosorbent assay in adults in general practitioners’ practices during one year. Sera were classified following manufacturer’s instructions as: strongly indicative of current/recent infection (≥1.5 optical density [OD] units); indicative of current/recent infection (≥1.0 OD units); seropositive (>0.3 OD units); or seronegative (≤0.3 OD units). Results: 1999 adults (60.6% female; mean age 47.4 ± 17.7 years) were included. 14.8% were seropositive, 1.1% were indicative of current/recent infection, and 0.1% were strongly indicative of current/recent infection. Conclusions: 85.2% of the subjects were seronegative and therefore susceptible to pertussis infection. Approximately 1% was suspicious of current/recent pertussis infection, potentially transmissible to susceptible young infants. Vaccination of adults is a key way to indirectly protect infants. Orv Hetil. 2018; 159(13): 503–510.

scholarly journals The relationship between mucosal immunity, nasopharyngeal carriage, asymptomatic transmission and the resurgence of Bordetella pertussis

F1000Research ◽  
2017 ◽  
Vol 6 ◽  
pp. 1568 ◽  
Author(s):  
Christopher Gill ◽  
Pejman Rohani ◽  
Donald M Thea
Keyword(s):  
Bordetella Pertussis ◽  
Mucosal Immunity ◽  
Whooping Cough ◽  
Critical Factor ◽  
Nasopharyngeal Carriage ◽  
Whole Cell ◽  
The Us ◽  
Acellular Vaccines ◽  
The Uk ◽  
The Relationship

The incidence of whooping cough in the US has been rising slowly since the 1970s, but the pace of this has accelerated sharply since acellular pertussis vaccines replaced the earlier whole cell vaccines in the late 1990s. A similar trend occurred in many other countries, including the UK, Canada, Australia, Ireland, and Spain, following the switch to acellular vaccines. The key question is why. Two leading theories (short duration of protective immunologic persistence and evolutionary shifts in the pathogen to evade the vaccine) explain some but not all of these shifts, suggesting that other factors may also be important. In this synthesis, we argue that sterilizing mucosal immunity that blocks or abbreviates the duration of nasopharyngeal carriage of Bordetella pertussis and impedes person-to-person transmission (including between asymptomatically infected individuals) is a critical factor in this dynamic. Moreover, we argue that the ability to induce such mucosal immunity is fundamentally what distinguishes whole cell and acellular pertussis vaccines and may be pivotal to understanding much of the resurgence of this disease in many countries that adopted acellular vaccines. Additionally, we offer the hypothesis that observed herd effects generated by acellular vaccines may reflect a modification of disease presentation leading to reduced potential for transmission by those already infected, as opposed to inducing resistance to infection among those who have been exposed.

scholarly journals Detection of Bordetella pertussis from Clinical Samples by Culture and End-Point PCR in Malaysian Patients

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Tan Xue Ting ◽  
Rohaidah Hashim ◽  
Norazah Ahmad ◽  
Khairul Hafizi Abdullah
Keyword(s):  
Bordetella Pertussis ◽  
Insertion Sequence ◽  
Whooping Cough ◽  
Culture Method ◽  
Clinical Samples ◽  
Old Patients ◽  
Clinical Specimens ◽  
End Point ◽  
Promoter Gene ◽  
Adolescents And Adults

Pertussis or whooping cough is a highly infectious respiratory disease caused by Bordetella pertussis. In vaccinating countries, infants, adolescents, and adults are relevant patients groups. A total of 707 clinical specimens were received from major hospitals in Malaysia in year 2011. These specimens were cultured on Regan-Lowe charcoal agar and subjected to end-point PCR, which amplified the repetitive insertion sequence IS481 and pertussis toxin promoter gene. Out of these specimens, 275 were positive: 4 by culture only, 6 by both end-point PCR and culture, and 265 by end-point PCR only. The majority of the positive cases were from ≤3 months old patients (77.1%) (). There was no significant association between type of samples collected and end-point PCR results (). Our study showed that the end-point PCR technique was able to pick up more positive cases compared to culture method.

scholarly journals Assays for Determining Pertussis Toxin Activity in Acellular Pertussis Vaccines

Toxins ◽  
2019 ◽  
Vol 11 (7) ◽  
pp. 417 ◽  
Author(s):  
Kevin Markey ◽  
Catpagavalli Asokanathan ◽  
Ian Feavers
Keyword(s):  
Molecular Structure ◽  
Quality Control ◽  
Virulence Factor ◽  
Pertussis Toxin ◽  
Bordetella Pertussis ◽  
Whooping Cough ◽  
Physiological Effects ◽  
Whole Cell ◽  
Acellular Vaccines ◽  
Main Component

Whooping cough is caused by the bacterium Bordetella pertussis. There are currently two types of vaccines that can prevent the disease; whole cell vaccines (WCV) and acellular vaccines (ACV). The main virulence factor produced by the organism is pertussis toxin (PTx). This toxin is responsible for many physiological effects on the host, but it is also immunogenic and in its detoxified form is the main component of all ACVs. In producing toxoid for vaccines, it is vital to achieve a balance between sufficiently detoxifying PTx to render it safe while maintaining enough molecular structure that it retains its protective immunogenicity. To ensure that the first part of this balancing act has been successfully achieved, assays are required to accurately measure residual PTx activity in ACV products accurately. Quality control assays are also required to ensure that the detoxification procedures are robust and stable. This manuscript reviews the methods that have been used to achieve this aim, or may have the potential to replace them, and highlights their continuing requirement as vaccines that induce a longer lasting immunity are developed to prevent the re-occurrence of outbreaks that have been observed recently.

Sign in / Sign up

Export Citation Format

Share Document